|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009402,
umls-concept:C0016360,
umls-concept:C0030705,
umls-concept:C0069717,
umls-concept:C0087111,
umls-concept:C0205179,
umls-concept:C0239307,
umls-concept:C1274040,
umls-concept:C1423743,
umls-concept:C1524062,
umls-concept:C2728259
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2000-2-10
|
|
pubmed:abstractText |
To provide evidence for the therapeutic efficacy of oxaliplatin (Eloxatin) when given as a 2-6-hour i.v. infusion, alone or in combination with 5-fluorouracil/folinic acid (5-FU +/- FA) in patients with advanced colorectal carcinoma (ACRC) who have failed 5-FU-based therapy. To confirm the safety of the drug and its combination in an extended-access context.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:AndréTT,
pubmed-author:BensmaïneM AMA,
pubmed-author:BleibergHH,
pubmed-author:BrienzaSS,
pubmed-author:CvitkovicEE,
pubmed-author:DucreuxMM,
pubmed-author:FrançoisEE,
pubmed-author:GamelinEE,
pubmed-author:ItzhakiMM,
pubmed-author:LouvetCC,
pubmed-author:MartyMM,
pubmed-author:SégalVV,
pubmed-author:SouliéPP,
pubmed-author:de BraudFF
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1311-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10631458-Adult,
pubmed-meshheading:10631458-Aged,
pubmed-meshheading:10631458-Analysis of Variance,
pubmed-meshheading:10631458-Antimetabolites, Antineoplastic,
pubmed-meshheading:10631458-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10631458-Cohort Studies,
pubmed-meshheading:10631458-Colorectal Neoplasms,
pubmed-meshheading:10631458-Confidence Intervals,
pubmed-meshheading:10631458-Dose-Response Relationship, Drug,
pubmed-meshheading:10631458-Drug Administration Schedule,
pubmed-meshheading:10631458-Europe,
pubmed-meshheading:10631458-Female,
pubmed-meshheading:10631458-Fluorouracil,
pubmed-meshheading:10631458-Follow-Up Studies,
pubmed-meshheading:10631458-Humans,
pubmed-meshheading:10631458-Infusions, Intravenous,
pubmed-meshheading:10631458-Male,
pubmed-meshheading:10631458-Middle Aged,
pubmed-meshheading:10631458-Neoplasm Metastasis,
pubmed-meshheading:10631458-Organoplatinum Compounds,
pubmed-meshheading:10631458-Salvage Therapy,
pubmed-meshheading:10631458-Severity of Illness Index,
pubmed-meshheading:10631458-Survival Analysis,
pubmed-meshheading:10631458-Survival Rate,
pubmed-meshheading:10631458-Treatment Outcome
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.
|
|
pubmed:affiliation |
Debiopharm, Charenton le Pont, Gentilly, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't
|
